HF2930

Purpose of the Bill

The bill aims to support research into amyotrophic lateral sclerosis (ALS) by reallocating funds through the University of Minnesota to partner with the Mayo Clinic for further study. It seeks to build on past appropriations to improve ALS research outcomes and ultimately find a cure for the disease.

Main Provisions

• Cancellation of Previous Appropriations: The bill cancels $15 million previously allocated to the Office of Higher Education for ALS research under past laws.

• New Funding Allocation: In fiscal year 2026, $15 million is appropriated from the general fund to the University of Minnesota's Board of Regents to collaborate with the Mayo Clinic on ongoing ALS research. This is a one-time appropriation with funds available until June 30, 2029.

• Annual Reporting Requirement: Starting January 15, 2026, and continuing annually until January 15, 2030, or until all funds are used, the University of Minnesota must report to the legislature on how these funds are being utilized in the partnership for ALS research.

Significant Changes to Existing Law

• Repeal of Previous Legislation: The bill repeals the sections of previous laws that outlined specific appropriations and grant distribution for ALS research through the Office of Higher Education.

• Shift in Research Administration: The focus shifts from the Office of Higher Education administering competitive grants to a direct partnership model between the University of Minnesota and the Mayo Clinic.

Relevant Terms

• ALS (Amyotrophic Lateral Sclerosis)
• University of Minnesota
• Mayo Clinic
• Appropriation
• Higher Education
• Research Funding
• Legislative Reporting
• Repeal